Summary: In a prespecified, descriptive subgroup analysis of a phase 2 trial enrolling 387 adults with a BMI of at least 27 kg/m² and without diabetes, once-weekly survodutide was associated with reductions in bodyweight and waist circumference across subgroups defined by sex and baseline BMI. Females showed greater reductions than males, and lower baseline BMI was linked to greater proportional weight loss; no formal significance testing was reported.
PICO Summary
| Element | Detail |
|---|---|
| Population | 387 adults aged 18 to 75 years with a BMI of at least 27 kg/m² and without diabetes; multicentre, double-blind phase 2 randomised controlled trial (NCT04667377). |
| Intervention | Once-weekly subcutaneous survodutide (glucagon/GLP-1 receptor dual agonist) at 0.6, 2.4, 3.6 or 4.8 mg over 46 weeks (20-week dose escalation, 26-week maintenance); four active arms, randomised 1:1:1:1:1. |
| Comparison | Matching placebo (one of five equal arms); efficacy and safety compared within prespecified subgroups defined by sex and baseline BMI. |
| Outcome | Data were analysed descriptively, with no p values, confidence intervals or significance tests reported. After 46 weeks, females had greater reductions in bodyweight and waist circumference than males. Participants with lower baseline BMI had greater proportional bodyweight reductions, while the trend reversed for waist circumference. Adverse-event rates were comparable across sex and BMI subgroups, with nausea the most frequent gastrointestinal event. No ARR or NNT is derivable from this descriptive analysis. |
Expert Commentary
This is a prespecified but descriptive subgroup analysis of a phase 2 dose-finding trial, and it should be read as hypothesis-generating rather than confirmatory. The headline observations are biologically plausible: greater weight and waist reductions were seen in females than in males, and proportional weight loss was larger in those starting at a lower BMI. However, because the data were analysed descriptively, no p values, confidence intervals or interaction tests were reported, so it cannot be concluded that survodutide works meaningfully differently by sex or BMI. The verdict is that the signal is interesting but unproven. The single most important limitation is the absence of inferential statistics, which leaves these subgroup contrasts vulnerable to chance and to the modest per-cell sample sizes that subdividing 387 participants across four doses and two factors inevitably produces. The trial was sponsored by the manufacturer, with several authors employed by the sponsor, and the effect sizes are large, both of which warrant cautious interpretation pending phase 3 confirmation. Can I use this with my patients? Not yet; survodutide remains investigational, and these subgroup patterns are not a basis for sex-tailored or BMI-tailored dosing. Adequately powered phase 3 trials with prespecified interaction testing are needed before any differential expectation is set.
References
le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hussain SA, Hennige AM. Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m² in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist. Diabetes Obes Metab. 2025;27(4):1773-1782. doi:10.1111/dom.16167